About SiteOne Therapeutics
SiteOne Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2010 by John V. Mulcahy, and was acquired by Lilly in May 2025. NaV1.7 inhibitors are developed for acute and chronic pain treatment. SiteOne Therapeutics has raised $123.78 million across 13 funding rounds from investors including Amgen, Lilly and NIH. Its chief executive, as recorded, is John V. Mulcahy. SiteOne Therapeutics offers products and services including STC-004. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its legal entity is SiteOne Therapeutics, Inc. Its competitors include Flexion Therapeutics, Eliem Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.
Company details
SiteOne Therapeutics was founded in 2010 in San Francisco, United States, with operations centered in the biotechnology sector for pain management. Selective NaV1.7 inhibitors, derived from naturally occurring small molecules, are advanced as therapeutic candidates. The lead product, targeting moderate to severe pain, is currently in pre-clinical trials. Additional applications include long-acting analgesics and PET imaging diagnostics for various pain conditions.
- Headquarters San Francisco, United States
- Founders John V. Mulcahy
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website siteonetherapeutics.com
- Social LinkedIn
- Acquired by Lilly (May 2025)
- Legal Name Siteone Therapeutics, Inc.
Products & Services of SiteOne Therapeutics
SiteOne Therapeutics offers a comprehensive portfolio of products and services, including STC-004.
Inhibitor targeting NaV1.8 for treating acute and chronic pain.
Funding Insights of SiteOne Therapeutics
SiteOne Therapeutics has successfully raised a total of $123.78M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $123.78M
- Total Rounds 13
- Last Round Series C β $100M
- First Round $3.12M
(Dec 2012)
- Investors Count 15
Latest 10 of 13 funding rounds of SiteOne Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $100M | Series C | β | Novo Holdings | |
| Mar 2024 | $6M | Series B | β | β | β |
| May 2023 | $15M | Grant | β | β | |
| Sep 2021 | $1.64M | Grant | β | β | |
| May 2019 | $1.53M | Grant | β | β | |
| Sep 2017 | $1M | Grant | β | β | |
| Jan 2017 | $15M | Series B | β | Amgen, Mission Bay Capital | |
| Sep 2015 | $1.71M | Grant | β | β | |
| Jul 2015 | $1.28M | Series A | β | β | |
| Sep 2014 | $1.5M | Series A | β | Sears Capital Management |
16 investors in total: 16 institutional.
Investors in SiteOne Therapeutics
SiteOne Therapeutics has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Lilly and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Limited information is provided about BSQUARED CAPITAL's activities. | bsq-c.com | |||
Venture capital investments are provided to technology-driven startups. | nextfrontiercapital.com | Bozeman, United States | ||
| 2m.com | ||||
A venture investment firm focused on life sciences is operated. | 1994 | searscapital.net | ||
| biobrit.com | ||||
| zipartners.com | ||||
US focused VC firm | missionbaycapital.com | San Francisco, United States |
Investor details for SiteOne Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SiteOne Therapeutics
20 people are tracked at SiteOne Therapeutics (4 in leadership, 15 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
John V. Mulcahy | Co-Founder & CEO | Leadership |
Joanne Bryce | Interim Chief Financial Officer | Leadership |
John C. Hunter | Chief Scientific Officer | Leadership |
Brian Wakabayashi | Vice President, Financial Planning And Analysis | Leadership |
Michael C. Rowbotham | Scientific Advisor | Board & advisors |
Brendan Canning | Scientific Advisor | Board & advisors |
Rick Orr | Director | Board & advisors |
Lowell E. Sears | Director | Board & advisors |
Peter Dicpinigaitis | Scientific Advisor | Board & advisors |
Frank Porreca | Scientific Advisor | Board & advisors |
Stephen Wexler | Scientific Advisor | Board & advisors |
Stephen G. Waxman | Scientific Advisor | Board & advisors |
Stan E. Abel | Director | Board & advisors |
Scott Braunstein | Director | Board & advisors |
Will Price | Director | Board & advisors |
Gary D. Novack | Scientific Advisor | Board & advisors |
Bradley J. Undem | Scientific Advisor | Board & advisors |
Justin Du Bois | Director | Board & advisors |
Anthony Ford | Scientific Advisor | Board & advisors |
Anne Mcreynolds Martin | Controller | Team |
Complete people profiles for SiteOne Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SiteOne Therapeutics
4 dated milestones of SiteOne Therapeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded SiteOne Therapeutics is founded.
- Funding First funding round of $3.1M.
- Funding Latest funding round, Series C, of $100.0M.
- Exit Acquired by Lilly.
Competitors of SiteOne Therapeutics
SiteOne Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Eliem Therapeutics and Zogenix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. |
Detailed competitors of SiteOne Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SiteOne Therapeutics
Websites that share an audience with SiteOne Therapeutics (siteonetherapeutics.com).
Websites whose visitors overlap most with SiteOne Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| r2mpharma.com | 100% | 2.9K | #4,331,217 | View details | |
| circlepharma.com | 98% | 2.8K | #6,088,315 | View details | |
| corvuspharma.com | 98% | 13.6K | #3,366,661 | View details | |
| theranova.com | 98% | View details | |||
| mandalmed.com | 97% | 1.3K | #14,142,095 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 31 similar websites and full traffic analytics for SiteOne Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as SiteOne Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Siteone Therapeutics
Complete news archive for SiteOne Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SiteOne Therapeutics
SiteOne Therapeutics was founded in 2010 and raised its 1st funding round 2 years after it was founded.
SiteOne Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
John V. Mulcahy is the CEO of SiteOne Therapeutics, as recorded in our data. They have also founded this company.
SiteOne Therapeutics is a funded company, having raised a total of $123.78M across 13 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Dec 2012.
SiteOne Therapeutics was founded in 2010 in San Francisco, United States, with operations centered in the biotechnology sector for pain management. Selective NaV1.7 inhibitors, derived from naturally occurring small molecules, are advanced as therapeutic candidates. The lead product, targeting moderate to severe pain, is currently in pre-clinical trials. Additional applications include long-acting analgesics and PET imaging diagnostics for various pain conditions.
SiteOne Therapeutics's top competitors include Flexion Therapeutics, Zogenix and Eliem Therapeutics.
SiteOne Therapeutics offers STC-004.
SiteOne Therapeutics operates through Siteone Therapeutics, Inc..
Yes. SiteOne Therapeutics was acquired by Lilly in May 2025.

